Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of XXXX .

@entity1 @entity483 @entity8721 @entity111 @entity134 @entity194
Elidel is a @entity134 -free cream containing a 1% strength of the topical immunomodulator pimecrolimus. Elidel was specifically developed as a treatment for @entity483 ( @entity483 ) and is approved for use in @entity1 as young as 2 years of age. The production of inflammatory cytokines by activated T cells in skin is thought to play an important role in the pathogenesis of @entity483 . Elidel potently suppresses cytokine production by dermal T cells without significantly impairing systemic immune responses. Elidel does not cause steroid-associated local effects, such as @entity194 , striae, or @entity8721 . In randomized controlled clinical studies, twice-daily application of Elidel was shown to significantly improve the signs and symptoms of @entity483 in @entity1 , @entity1 , and adults. The clinical effect of Elidel on @entity111 , the most troublesome symptom of @entity483 , can be observed within 1 week of therapy and is maintained for the duration of treatment. Elidel is well tolerated; the risk of application-site reactions, such as itching or burning, is comparable with that of the vehicle. Adverse effects were generally mild in @entity1 receiving Elidel and occurred at rates comparable with those in @entity1 receiving vehicle treatment. In a 1-year study, Elidel significantly reduced the incidence of flares when used at the first signs and symptoms of acute @entity483 . As a result, overall corticosteroid use to treat flares was significantly lower in @entity1 using Elidel for early intervention.
